Distinguishing primary from secondary synovial osteochondromatosis involves differences in pathological features [4], proliferating cell nuclear antigen (PCNA) positivity rate in immunological testing [5], and fibroblast growth factor (FGF9) expression [6,7]. This evidence concerns the gene FGF9 and synovial chondromatosis.